Efficacy and safety of recombinant human serum albumin in refractory edema accompanying nephrotic syndrome
ASN 30th Annual Meeting, San Antonio
J Am Soc Nephrol (Sep) 8:100A 1997
Recombinant human serum albumin (rHSA) using Pichia pastoris has been shown to be safe and effective in non-clinical studies. In this study, rHSA (12.5-25 g/d x 4-10 d) was utilized in 42 patients with nephrotic syndrome and diuretic-refractory edema. Serum albumin increased from 2.1 ± 0.5 to 2.9 ± 0.8 g/dl, which was accompanied by an increase in urine volume (1.1 to 1.7 L/d) and a decrease in body weight (58.2 to 54.7 kg). The authors conclude that rHSA is clinically useful for the treatment of edema in nephrotic syndrome.
Comment: Albumin infusion is frequently useful in symptomatic patients with nephrotic syndrome. However, its use has been limited by high cost and transient effects. Large-scale production of recombinant human serum albumin will make it feasible to administer albumin in a more cost-effective manner. (David J. Leehey, M.D., Loyola University at Chicago)
To go back use the BACK button on your browser. Otherwise click on the desired link to this article below:
ASN 30th Annual Meeting, San Antonio
Nephrotic Syndrome : Treatment (CEI, indomethacin, lipid drugs)